Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01984892 · ClinicalTrials.gov registry record · Phase 2
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
A Phase 2 study, sponsored by Nina Bhardwaj.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01984892 is a Phase 2 study that was terminated before completion, run by Nina Bhardwaj. The registered enrollment target is 8 participants.
The verdict
NCT01984892, a Phase 2 study, was terminated before completion, sponsored by Nina Bhardwaj.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle. Poly-ICLC is a compound that has been used to help the body in its fight against cancer.
Interventions
- DRUG Poly-ICLC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01984892
The ClinicalTrials.gov registry entry for NCT01984892 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nina Bhardwaj, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Poly-ICLC is the first listed.
NCT01984892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01984892 about?
NCT01984892 is a clinical study titled "Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)". The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle. Poly-ICLC is a compound that has been used to help the body in its fight against cancer.
What is the current status of trial NCT01984892?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-11. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01984892?
The interventions under investigation include: Poly-ICLC (DRUG).
Who is sponsoring clinical trial NCT01984892?
This trial is sponsored by Nina Bhardwaj, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.